Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO) Applies Broad Stem Cell IP Portfolio To Three Key Markets 0 comments
    Jun 14, 2013 5:36 PM | about stocks: ISCO

    Biotech small-cap International Stem Cell Corp. uses unfertilized eggs to develop therapies to treat diseases of the brain, liver, and the eye. By using unfertilized eggs to create human pluripotent stem cells, the company's core technology avoids the controversial use of viable human embryos.

    As noted above, the company is focused on three key markets:

    The company is in pre-clinical stages for its treatment of Parkinson's disease. Parkinson's disease is the second most prevalent neurodegenerative diseases, effecting 4 percent of the population over the age of 50. The company says the origin of the disease and its relative localization in the brain makes this an attractive target for stem cell therapy.

    Chronic liver disease, including hepatitis C, is the third most common cause of death due to chronic diseases in persons 35 to 64 years old. The company is in pre-clinical stage for its treatment of liver disease with stem-cell derived hepatocytes, a cell that makes up 70-85 percent of the liver's cytoplasmic mass.

    The company notes a large unmet medical need for the treatment of blindness with corneal tissue. Approximately 10 million people in the world are blind because of damage to their cornea. ISCO is in pre-clinical stage to produce cornea tissue implants. The company has developed and filed patents on a process that creates human corneal tissue from parthenogenetic stem cells, closely resembling a human cornea in structure and cell types.

    As of April 13, 2012, the company had 90 pending patent applications across eight patent families, and three pending patents related to its skin care products. ISCO also has licensed a portfolio of 128 international patents or patent applications across 30 patent families.

    For more information, visit internationalstemcell.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.